文献速递心脑血管急症消化、代谢与肾脏急症

高复发风险静脉血栓栓塞延长治疗:减量对比全量直接口服抗凝药的非劣效性多中心随机开放标签盲法终点试验

Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
PubMed 文献 · Lancet · 2025-01-01
一句话结论高复发风险静脉血栓栓塞延长抗凝中,减量直接口服抗凝药未达非劣效标准,但复发率低且大出血或临床相关出血明显减少,作者认为可作为选项。

RENOVE为法国47家医院开展的非劣效、多中心、随机、开放标签、盲法终点试验,纳入2768例已完成6-24个月全剂量抗凝且需延长抗凝的急性症状性静脉血栓栓塞门诊患者,随机接受减量(阿哌沙班2.5 mg每日两次或利伐沙班10 mg每日一次)或全量(阿哌沙班5 mg每日两次或利伐沙班20 mg每日一次)治疗。中位随访37.1个月,减量组复发静脉血栓栓塞5年累积发生率2.2% vs 全量组1.8%(调整HR 1.32,95%CI 0.67-2.60;绝对差0.40%,95%CI -1.05至1.85;非劣效p=0.23),未达非劣效标准;大出血或临床相关出血减量组9.9% vs 全量组15.2%(调整HR 0.61,95%CI 0.48-0.79)。作者认为两组复发率均低且减量组出血明显减少,该方案可作为选项,需进一步研究识别不应减量的亚组。

要点

  • 减量组复发静脉血栓栓塞5年累积发生率2.2%(95%CI 1.1-3.3)vs 全量组1.8%(95%CI 0.8-2.7),调整HR 1.32(95%CI 0.67-2.60),非劣效检验p=0.23,未达非劣效标准。
  • 大出血或临床相关出血减量组5年累积发生率9.9%(95%CI 7.7-12.1)vs 全量组15.2%(95%CI 12.8-17.6),调整HR 0.61(95%CI 0.48-0.79)。
  • 减量组死亡35例(5年累积发生率4.3%,95%CI 2.6-6.0)vs 全量组54例(6.1%,95%CI 4.3-8.0)。
  • 减量组374例(27.0%)vs 全量组420例(30.3%)发生严重不良事件;减量组1136例(82.1%)vs 全量组1150例(83.0%)发生不良事件。
  • 作者认为两组复发率均低且减量组临床相关出血明显减少,该减量方案可作为选项;需进一步研究识别不应减量的亚组。

适用人群与场景

  • 年龄18岁及以上、急性症状性静脉血栓栓塞(肺栓塞或近端深静脉血栓)的门诊患者,且已接受6-24个月不间断全剂量抗凝、需延长抗凝治疗。
  • 纳入的高复发风险类别包括:首次无诱因静脉血栓栓塞、复发性静脉血栓栓塞、存在持续危险因素,或其他被考虑为高复发风险的临床情况。

处置流程与药物剂量

  • 减量组:口服阿哌沙班2.5 mg每日两次,或利伐沙班10 mg每日一次。
  • 全量组:口服阿哌沙班5 mg每日两次,或利伐沙班20 mg每日一次。
  • 随机化按中心、直接口服抗凝药种类和抗血小板药物分层,采用交互式网络应答系统集中随机(1:1),区组长度不等。

研究设计与关键结果

  • RENOVE为非劣效、研究者发起、多中心、随机、开放标签、盲法终点试验,在法国47家医院开展,2017年11月2日至2022年7月6日纳入2768例,随机分至减量组(n=1383)或全量组(n=1385);970例(35.0%)女性,1797例(65.0%)男性,1例(<0.1%)性别未报告;中位随访37.1个月(IQR 24.0-48.3)。
  • 主要终点 symptomatic recurrent venous thromboembolism(症状性复发性静脉血栓栓塞,包括复发性致死或非致死性肺栓塞或孤立性近端深静脉血栓):减量组19/1383例,5年累积发生率2.2%(95%CI 1.1-3.3);全量组15/1385例,5年累积发生率1.8%(95%CI 0.8-2.7);调整HR 1.32(95%CI 0.67-2.60);绝对差0.40%(95%CI -1.05至1.85);非劣效检验p=0.23。
  • 大出血或临床相关出血:减量组96例,5年累积发生率9.9%(95%CI 7.7-12.1);全量组154例,5年累积发生率15.2%(95%CI 12.8-17.6);调整HR 0.61(95%CI 0.48-0.79)。
  • 不良事件:减量组1136/1383例(82.1%)vs 全量组1150/1385例(83.0%);严重不良事件:减量组374例(27.0%)vs 全量组420例(30.3%)。
  • 死亡:减量组35例,5年累积发生率4.3%(95%CI 2.6-6.0);全量组54例,5年累积发生率6.1%(95%CI 4.3-8.0)。

证据类型、等级与局限

  • 证据类型:非劣效、多中心、随机、开放标签、盲法终点试验(RENOVE),主要终点设90%把握度排除HR 1.7;主要终点及前两项次要终点纳入层级检验程序。
  • 局限:减量直接口服抗凝药未达到非劣效标准;作者指出需要进一步研究以识别不应降低抗凝剂量的亚组。

对床旁实践的改变

  • 对于已完成6-24个月全剂量抗凝且需延长抗凝的高复发风险静脉血栓栓塞患者,作者认为减量直接口服抗凝药(阿哌沙班2.5 mg每日两次或利伐沙班10 mg每日一次)可作为选项,因两组复发率均低且减量组临床相关出血明显减少。
  • 作者指出减量未满足非劣效标准,且需进一步研究识别不应减量的亚组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.

METHODS: RENOVE was a non-inferiority, investigator-initiated, multicentre, randomised, open-label, blinded endpoint trial done in 47 hospitals in France. Ambulatory patients aged 18 years or older with acute symptomatic venous thromboembolism (pulmonary embolism or proximal deep vein thrombosis) who had received 6-24 uninterrupted months of full-dose anticoagulation and for whom extended anticoagulation has been indicated were eligible. Eligible participants were categorised as having either a first unprovoked venous thromboembolism, recurrent venous thromboembolism, presence of persistent risk factors, or other clinical situations considered to be a high risk of recurrence. Participants were randomly assigned (1:1) to receive oral treatment with either a reduced dose of apixaban (2·5 mg twice daily) or rivaroxaban (10 mg once daily) or a full dose of apixaban (5 mg twice daily) or rivaroxaban (20 mg once daily) using a centralised randomisation procedure with an interactive web response system. The sequence generation method was a computerised random number generator and was balanced by blocks of different sizes. Randomisation was stratified by centre, type of direct oral anticoagulant, and antiplatelet drug. Physicians and participants were unmasked to treatment allocation; recurrent venous thromboembolism, clinically relevant bleeding, and all-cause death were adjudicated by an independent committee blinded to treatment allocation. The primary outcome was symptomatic recurrent venous thromboembolism, including recurrent fatal or non-fatal pulmonary embolism or isolated proximal deep vein thrombosis (non-inferiority hypothesis 90% power to exclude a hazard ratio [HR] of 1·7). The primary outcome and first two secondary outcomes were included in a hierarchical testing procedure. This trial is registered with ClinicalTrials.gov, NCT03285438.

FINDINGS: From Nov 2, 2017, to July 6, 2022, 2768 patients were enrolled and randomly assigned to the reduced-dose group (n=1383) or the full-dose group (n=1385). 970 (35·0%) participants were female, 1797 (65·0%) were male, and one (<0·1%) had sex not reported. Median follow-up was 37·1 months (IQR 24·0-48·3). Recurrent venous thromboembolism occurred in 19 of 1383 patients in the reduced-dose group (5-year cumulative incidence 2·2% [95% CI 1·1-3·3]) versus 15 of 1385 patients in the full-dose group (5-year cumulative incidence 1·8% [0·8-2·7]; adjusted HR 1·32 [95% CI 0·67-2·60]; absolute difference 0·40% [95% CI -1·05 to 1·85]; p=0·23 for non-inferiority). Major or clinically relevant bleeding occurred in 96 patients in the reduced-dose group (5-year cumulative incidence 9·9% [95% CI 7·7-12·1]) and 154 patients in the full-dose group (5-year cumulative incidence 15·2% [12·8-17·6]; adjusted HR 0·61 [95% CI 0·48-0·79]). 1136 (82·1%) of 1383 patients in the reduced-dose group and 1150 (83·0%) of 1385 in the full-dose group had an adverse event; 374 (27·0%) patients in the reduced-dose group and 420 (30·3%) in the full-dose group has a serious adverse event. 35 (5-year cumulative incidence 4·3% [95% CI 2·6-6·0]) patients in the reduced-dose group and 54 (5-year cumulative incidence 6·1% [4·3-8·0]) patients in the full-dose group died during the study period.

INTERPRETATION: In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence rates in both groups and substantial reduction of clinically relevant bleeding with the reduced dose could support this regimen as an option. Further research will be needed to identify subgroups for whom the anticoagulation dose should not be reduced.

FUNDING: French Ministry of Health.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025. PMID: 40023651. doi:10.1016/S0140-6736(24)02842-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。